Adaptive Biotechnologies Corporation
ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$13.88
Price+8.02%
$1.03
1Y
Price
Market Cap
$2.137b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-9.0%
EBITDA Margin-18.9%
Net Profit Margin+2.0%
Free Cash Flow Margin-9.0%
EBITDA Margin-18.9%
Net Profit Margin+2.0%
Free Cash Flow MarginRevenue
$276.976m
+54.8%
1y CAGR+17.3%
3y CAGR+18.0%
5y CAGREarnings
-$59.499m
+62.7%
1y CAGR+26.5%
3y CAGR+20.7%
5y CAGREPS
-$0.39
+63.0%
1y CAGR+12.6%
3y CAGR+17.3%
5y CAGRBook Value
$225.001m
$512.736m
Assets$287.735m
Liabilities$280.584m
DebtDebt to Assets
54.7%
-7.5x
Debt to EBITDAFree Cash Flow
-$48.945m
+50.5%
1y CAGR+36.0%
3y CAGR+32.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company